Clear. Simple. Back in business.
Turnkey Employee COVID-19 Testing Programs
Quest’s Employee COVID-19 Testing program provides the healthcare expertise you need to help protect your employees, productivity, and profitability. Our simple-to-execute, fully customizable solutions are focused on keeping your workforce safe and healthy on the job. Straightforward test results and robust data reporting arm you and your staff with the insights to make informed staffing decisions about coming to work—even before your team is fully vaccinated.
Accurate, reliable testing options
- Molecular active infection swab tests detect or confirm the presence of the virus with supervised or unsupervised self-collection at home, at work, or at a Quest location
- IgG antibody blood tests detect antibodies that show if an individual may have had a prior or recent infection
Medical oversight provider PWNHealth® is available to provide guidance on medical decisions and follow-up care.
Quest will support continued testing efforts as long as COVID-19 presents a risk to your business.
Get Started Now
Fill out the form below and one of our representatives will work with you to create a custom employee COVID-19 testing plan that can help your business stay up and running at full capacity.
If you're a representative from a school or university, please click here.
Quest Diagnostics is the world’s leading provider of diagnostic information services
Scalable to meet your evolving needs:
Our size enables us to collect and analyze COVID-19 testing efforts expeditiously.
Stay up and running
Monitor for symptoms, provide ongoing testing, and isolate any active cases on-site.
Rescreen employees at regular intervals or after they return from time off.
Flexible to give you options:
Consider ongoing molecular swab tests, IgG antibody blood tests, and temperature checks for all staff.
IgG antibody blood tests are available at our nationwide network of over 2,200 Patient Service Centers.
Molecular active infection swab tests are offered via self-collection kits and can be observed by a telehealth provider as needed.
Intervention at key touchpoints:
Deploy molecular swab tests and IgG antibody blood tests to track overall positivity among employees.
Check symptomatic employees with molecular active infection swab testing.
Manage infection outbreaks with self-collection molecular tests and contactless drop-off and pickup.
Data and reporting solutions:
Digital onboarding process with intuitive steps makes it simple for employers to launch the program and for staff to register, make appointments, and check in.
Employees are alerted via email when test results are ready. The easy-to-understand results can be printed or shared.
Employer administrators can get daily email reports to review and verify employee participation status and results, while also adhering to privacy laws.
Employees should always discuss their signs and symptoms with their physicians as well as any positive test results.
Important information about COVID-19 antibody testing
The test is designed to detect antibodies to SARS-CoV-2, the virus that causes COVID-19. Antibodies are proteins that the body produces in response to infections. The antibodies can be produced even if a person has few or no symptoms during the infection.
It generally takes some time after infection for antibodies to be produced and become detectable in blood (sometimes up to 3 weeks). It is important to remember that we do not yet know whether having antibodies to SARS-CoV-2 will prevent against getting the infection again or if you are totally free of the virus. Antibodies are generally detectable in the blood for a period of time after a person has recovered from the infection and after the virus that caused the infection is no longer detectable by laboratory methods.
Sometimes the antibodies developed in response to an infection protect us from getting that same infection again. But, it is important to know that we do not yet know whether this is true for COVID-19. Even if you have recovered and have antibodies, there is a chance that you still have the virus and you can infect others, so it is still critical to keep taking measures to avoid getting infected again and/or spreading infection.
The antibody test is not meant for detecting an active infection. The swab test (sometimes also known as a molecular, RNA, or PCR test) should be used to test for active infection.
A negative antibody test result means that antibodies were not detected in your blood sample. This can have several possible meanings. It could mean that:
- You have not been infected with SARS-CoV-2, or
- You have been infected with SARS-CoV-2, but your antibodies have not reached a sufficient level for the test to be able to detect them, or
- You have been infected with SARS-CoV-2, but there has not been enough time for antibodies to develop (it can take up to 1 to 3 weeks to develop antibodies after someone is infected, sometimes longer).
A positive antibody test result means that antibodies were detected in your blood sample. This can have a couple of possible meanings. It could mean that:
- You have been infected with SARS-CoV-2 at some point in the past, or
- Uncommonly, you may have developed antibodies from an earlier infection with a different virus related to SARS-CoV-2 and the laboratory test cannot distinguish between these other virus antibodies and those antibodies generated in response to SARS-CoV-2.
COVID-19 testing statements
- The antibody tests have not been FDA cleared or approved;
- The antibody tests have been authorized by FDA under an EUA for use by authorized laboratories;
- The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens; and,
- The antibody tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- The cobas SARS-CoV-2 & Influenza A/B Test and the Quest SARS-CoV-2 RT-PCR test and other molecular tests (“Tests”) have not been FDA cleared or approved.
- The Tests have been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests. The Roche test has been authorized only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.
- The Roche test is only authorized for the duration of the declaration that circumstances exist justifying the authorized of the emergency use of in vitro diagnostics for detection and differentiation of SARS-CoV-2 virus, Influenza A, and Influenza B under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorized is terminated or revoked sooner.
- The Quest test and other molecular tests been authorized only for the detection of nucleic acid from SARSCoV-2, not for any other viruses or pathogens.
- The Quest test and other molecular tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.